DDInter596 DDInter927
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Doxorubicin {u} (Compound) treats {v} (Disease) stomach cancer
Doxorubicin {u} (Compound) binds {v} (Gene) AKR1A1
Doxorubicin {u} (Compound) upregulates {v} (Gene) P4HA2
Doxorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Anthracyclines
Doxorubicin {u} (Compound) downregulates {v} (Gene) TSKU
Doxorubicin {u} (Compound) causes {v} (Side Effect) Mucous membrane disorder
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) ABCC10
Doxorubicin (Compound) resembles Daunorubicin (Compound)
Doxorubicin (Compound) treats stomach cancer (Disease)
Doxorubicin (Compound) binds AKR1A1 (Gene)
Doxorubicin (Compound) upregulates P4HA2 (Gene)
Doxorubicin (Compound) is included by Anthracyclines (Pharmacologic Class)
Doxorubicin (Compound) downregulates TSKU (Gene)
Doxorubicin (Compound) causes Mucous membrane disorder (Side Effect)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene)
Doxorubicin (Compound) binds ABCC10 (Gene) and Doxorubicin (Compound) upregulates ABCC10 (Gene)